Wang, Sizhen
Zhang, Xiaohui
Zou, Xuemei
Wen, Maorong
Gan, Chi
Jiang, Xiaochun
Li, Min
Shen, Rongxi
Zhu, Daojun
Yao, Anlong
Fang, Yu
Fox, Bernard A.
Hu, Hong-Ming
Yu, Guangjie
Wang, Xinbo
Funding for this research was provided by:
Jiangsu Clinical Medical Center (innovation platform) construction project (YXZXA2016006, YXZXA2016006)
Shanghai Pujiang Program (20PJ1417400)
Article History
Received: 9 August 2022
Accepted: 18 November 2022
First Online: 27 November 2022
Declarations
:
: Xiaohui Zhang, Xuemei Zou, Maorong Wen, Chi Gan, Xiaochun Jiang, and Guangjie Yu are full-time employees of ImmuXell ltd. They have filed patent applications related to the TCR technology and could potentially receive licensing royalties. All other authors have no conflict of interest to declare. Hong-Ming Hu and Bernard A. Fox is the founder of UbiVAC, and UbiVAC is a potential licensee of technology developed in this study.
: Xiaohui Zhang, Xuemei Zou, Maorong Wen, Chi Gan, Xiaochun Jiang, and Guangjie Yu are full-time employees of ImmuXell ltd. They have filed patent applications related to the TCR technology and could potentially receive licensing royalties. All other authors have no conflict of interest to declare. Hong-Ming Hu and Bernard A. Fox is the founder of UbiVAC, and UbiVAC is a potential licensee of technology developed in this study.
: This study was approved by the Ethics Committee of Jinling Hospital (Nanjing, China), reference number 2020NJKY-020–01.